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Abstract
Aim: This study investigated the nosocomial blood stream infection (BSI) in the adult ICUs in
Assiut university hospitals to evaluate the rate of infection in different ICUs, causative
microorganisms, antimicrobial resistance, outcome of infection, risk factors, prevalence of
extended spectrum B-lactamase producing organisms and molecular typing of Klebsiella pneumoniae
strains to highlight the role of environment as a potential source of nosocomial BSI.
Methods: This study was conducted over a period of 12 months from January 2006 to December
2006. All Patients admitted to the different adult ICUs were monitored daily by attending physicians
for subsequent development of nosocomial BSI. Blood cultures were collected from suspected
patients to detect the causative organisms. After antimicrobial susceptibility testing, detection of
ESBLs was conducted among gram negative isolates. Klebsiella pneumoniae isolates were tested by
PCR to determine the most common group of B-lactamase genes responsible for resistance.
Klebsiella pneumoniae isolates from infected patients and those isolated from the environment
were typed by RAPD technique to investigate the role of environment in transmission of infection.
Results: The study included 2095 patients who were admitted to different ICUs at Assiut
University Hospitals from January 2006 to December 2006. Blood samples were collected from
infected patients for blood cultures. The colonies were identified and antibiotic sensitivities were
performed. This study showed that the rate of nosocomial BSI was 75 per 1000 ICU admissions
with the highest percentages in Trauma ICU (17%). Out of 159 patients with primary bloodstream
infection, 61 patients died representing a crude mortality rate of 38%. Analysis of the organisms
causing BSI showed that Gram positive organisms were reported in 69.1% (n = 121); MRSA was the
most prevalent (18.9%), followed by methicillin resistant coagulase negative Staphylococci (16%).
Gram negative bacilli were reported in 29.1% (n = 51). In this case, Klebsiella pneumoniae was the
most common (10.3%) followed Ec o l i(8.6%). Candida spp. was reported only in (1.7%) of isolates.
Antibiotics sensitivities of Gram positive organisms showed that these organisms were mostly
sensitive to vancomycin (90.1%), while Gram negative organisms were mostly sensitive to
imipenem (90.2%). In this study we tested Gram negative isolates for the production of the ESBL
enzyme and concluded that 64.7% (33/51) of patients' isolates and 20/135 (14.8%) environmental
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Open Accessisolates were confirmed to be ESBL producers. The type of b-lactamase gene was determined by
polymerase chain reaction which showed that SHV was the main type. Molecular typing was done
for 18 Klebsiella pneumoniae strains that caused nosocomial BSI and for the 36 Klebsiella
pneumoniae strains which were isolated from the environmental samples by the RAPD method.
The two environmental strains were identical, with one isolated from a patient, which confirms the
serious role of the hospital environment in the spread of infections.
Conclusion: Nosocomial BSI represents a current problem in Assiut University Hospitals, Egypt.
Problems associated with BSI include infection with multidrug resistant pathogens (especially
ESBLs) which are difficult to treat and are associated with increased mortality. Of all available anti-
microbial agents, carbapenems are the most active and reliable treatment options for infections
caused by ESBL isolates. However, overuse of carbapenems may lead to resistance of other Gram-
negative organisms.
Findings
Nosocomial infections (NIs) are infections that became
clinically evident after 48 hours of hospitalization and do
not originate from patient's original admitting diagnosis
[1]. These infections cause significant morbidity and
mortality and have a considerable impact on healthcare
costs.AmongalltypesofNIs,thenosocomialBSIcreatesa
serious health problem in hospitals all over the world. In
addition, patients admitted to ICUs carry an even higher
risk of nosocomial BSI than those admitted to other types
of units. Data from the surveillance and control of
pathogens of epidemiologic importance (SCOPE) sur-
veillance system in United States hospitals showed that
49.4% of all nosocomial BSI occurred in the ICU [2].
Reports on the incidence of BSI vary significantly,
reflecting differences in individual risk based on institu-
tion, co-morbid illnesses, length of stay, and hospital
location.Moreover,on anational level, nosocomial BSIis
the 10
th leading cause of death in the U.S. Approximately
250,000 cases of BSI occur in the U.S. annually [3].
In the last 30 years, the frequency, etiology, and
epidemiology of nosocomial BSI have changed with
the evolution of medical care, particularly among the
increasing number of hospitalized patients who require
intensive care. Nearly 75% of primary bloodstream
infections have been caused by Gram-negative bacilli.
This is due to the development of potent anti-staphylo-
coccal b-lactam agents. Staphylococcus aureus gave way to
Gram-negative bacilli, however, by the early 1980s;
Gram-positive cocci began to re-emerge as predominant
nosocomial pathogens [4].
Mortality and morbidity from infections are greater
when caused by antimicrobial-resistant bacteria. Enter-
obacteriaceae and non-fermentative Gram-negative
bacilli are of great concern because antimicrobial therapy
for infections due to these resistant pathogens remains a
clinical dilemma in hospitalized patients [5]. It is also
noted that there is an increase in the resistance among
Gram-negative bacilli to third generation cephalosporins
which is caused by expression of Extended-Spectrum
B-lactamase (ESBL) enzymes. Therefore infections due to
ESBL isolates continue to pose a challenge to infection
management world wide [6].
This study aimed at investigating the nosocomila BSI in
theadultintensivecareunitsinAssiutuniversityhospitals
to evaluate the rate of infection in different ICUs,
causative microorganisms, antimicrobial resistance, out-
come of infection, prevalence of extended spectrum
B-lactamase producing organisms and molecular typing
of Klebsiella pneumoniae s t r a i n st oh i g h l i g h tt h er o l eo ft h e
environment as a potential source of nosocomial BSI.
Methods
Study Design and Subjects
This study was approved by the ethical committee of our
institute and written informed consent was obtained
from all patients for publication of this manuscript.
Patients
The study was conducted over a period of 12 months
from January 2006 to December 2006 to all patients
admitted at different adult ICUs at Assiut University
Hospitals including: Coronary care unit (CCU), Chest
ICU, Tropical ICU, Neurological ICU, Internal Medicine
ICU, General ICU, Trauma ICU and Neurosurgical ICU.
All patients admitted at different adult intensive care
units (ICUs) were monitored daily by attending physi-
cians for subsequent development of nosocomial BSI,
which must meet at least one of the following criteria:
Criterion 1: Patient has a recognized pathogen cultured
from one or more blood cultures and the organism
cultured from blood is not related to an infection at
another site.
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or symptoms: fever (> 38°C), chills, or hypotension and
at least one of the following:
Commonskincontaminant(e.g.,diphtheroids,Bacillussp.,
coagulase-negative staphylococci, or micrococci) is cultured
from two or more blood cultures drawn on separate
occasions. The Signs and symptoms of infection appear 48
hoursto four days afteradmission,and there arenosignsor
symptoms of infection at the time of admission, proven by
history and clinical examination [7].
Controls: included 159 Patients admitted to different
ICUs during the same period but without any signs or
symptoms of infection. Each case was matched with one
control for age, sex and ICU specialty.
Environmental assessment: 475 environmental samples
were collected from walls, floors, beds, bedside tables,
and trays. These are the sites that we usually sample from
based on the protocol followed in our institute.
Contact precautions were taken into consideration for
the medical staff, hospital workers and visitors.
Sample collection
Bloodsamples:5to10mlofvenousbloodwascollectedfrom
patientsusingsterilesyringes.Bloodsampleswereinoculated
immediately under complete aseptic conditions into bottles
containing 50 ml of brain heart infusion broth [8].
Environmental samples: sterile cotton swabs were moisten
by a sterile physiological saline solution and used to collect
samples from walls, floors, beds, bedside tables, and trays.
Processing of samples
Blood samples: the blood culture bottles were incubated
aerobically at 37°C for 7 days. The bottles were examined
daily for evidence of bacterial growth as haemolysis, gas
production or turbidity above the red cell line. Sub-
cultures using sterile syringes were done on blood agar,
chocolate agar, MacConkey's agar and Bile Esculin Azide
agar daily for 7 days before reporting blood cultures as
negative [9]. Isolation of anaerobes is not considered.
Environmental samples: they were inoculated aerobi-
cally at 37°C for 24 hours on brain heart infusion broth
for enrichment and then sub-cultured on blood agar and
incubated for 24 hours at 37°C.
Identification of bacterial isolates
Identification of gram negative bacilli: gram negative
bacilli were identified by API 20E system (Biomeriux SA,
Montalien Vercica and France).
Identification of enterococcal isolates: suspected enter-
ococcal isolates on Bile Esculin Azide agar were
identified by the Colony morphology, Gram staining,
the catalase test, the PYR test (production of pyrrolidonyl
arylamidase), and the possession of Lancefield antigen D
by using commercially available latex agglutination
test. Omega Avipath Strep (Omega Diagnostica LTD.,
Scotland, UK).
Identification of staphylococcal isolates: according to
Louie et al. [10], staphylococci were identified by
standard methods including the gram stain, catalase
test and tube coagulase test. Samples were cultured on
Mannitol Salt Agar (MSA) (Oxoid, UK), where S. aureus
produces yellow colonies (1 mm in diameter) sur-
rounded by a yellow medium, and CNS forms
small orange colonies surrounded by a red or purple
medium [11].
Isolates which showed positive growth on Mannitol Salt
Agar plates were subcultured on an Oxacillin Resistant
Screening Agar Base (ORSAB) medium (Oxoid, UK) for
Detection of oxacillin resistance.
Antimicrobial Susceptibility testing by modified
Kirby-Bauer disc diffusion method: [10]
According to the protocol of the infection control lab,
the following antibiotics were used: Antibiotics for
Gram positive bacteria: B-Lactams (Ampicillin, Penicil-
lin G, Cefazoline, Amoxicillin/clavulanic acid, Ceftriax-
one, Cefotaxime and Oxacillin), Macrolides
(Erythromycin), Aminoglycosides (Amikacin, Gentami-
cin), Tetracyclines (Tetracycline), Quinolones (Cipro-
floxacin, Norfloxacin), Others (Chloramphenicol,
Clindamycin, Vancomycin, Teicoplanin, Trimethoprim/
sulfamethoxazole)
Antibiotics for Gram negative bacteria: B-Lactams
(Ampicillin, Penicillin G, Cefazoline, Amoxicillin/clavu-
lanic acid, Ceftriaxone, Ceftazidime, Piperacillin, Cefo-
perazone, Cefpodoxime, Cefuroxime, Aztreonam,
Imipenem) Aminoglycosides (Amikacin, Gentamicin,
Tobramycin), Tetracyclines (Tetracycline), Quinolones
(Ciprofloxacin, Norfloxacin), Others (Chloramphenicol,
Trimethoprim/sulfamethoxazole).
Detection of b-lactamase production
b-lactamase enzyme is detected among the gram negative
bacilli by the chromogenic method (Nitrocefin test).
Detection of Extended Spectrum B-Lactamases
Selective testing for ESBL production is considered for all
gram negative bacilli.
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Isolates that exhibited reduced susceptibility to one or
more of cefpodoxime, ceftazidime, aztreonam, cefotax-
ime or ceftriaxone were considered as potential produ-
cers of ESBL.
Confirmatory Tests:
The combined disk method or Inhibitor potentiated disc
diffusion test [12]: ceftazidime (30 μg) versus ceftazi-
dime/clavulanic acid (30 μg/10 μg), (Oxoid, UK), were
used as a phenotypic confirmatory test where a greater
than or equal to 5 mm increase in the zone diameter for
the antimicrobial agent tested in combination with
B-lactamase inhibitor versus its zone when tested alone
indicates ESBL production.
Double-Disk Synergy "DDS" Test [13]: where any
enhancement in the zone of inhibition between a beta-
lactam disk and one containing the beta lactamase
inhibitor was indicative of the presence of an ESBL.
ESBL – E – Test [14]: According to the manufacturer, a
ceftazidime MIC/ceftazidime clavulanic acid MIC ratio
which is equal to or greater than 8 indicates the presence
of ESBLs (positive test).
Determination of the type of b-lactamase by
polymerase chain reaction
In the present study, 18 Klebsiella pneumoniae strains
which have caused primary bloodstream infection were
investigated to determine the probable type of
b-lactamase enzyme which was responsible for resis-
tance. The isolates were picked up and tested for TEM,
SHV, CTX-M-1, TOHO-1 genes by the PCR method [15].
Molecular typing by Random Amplified Polymorphic
DNA (RAPD)
18Klebsiella pneumoniae strains isolated from nosocomialBSI
cases and 36 Klebsiella pneumoniae strains isolated from the
environmental samples were typed by the RPAD method.
RAPD is a method for detecting strain differences. Its
ability to type a wide variety of bacterial strains in a short
time suggests that it will be a useful molecular
epidemiological tool [16].
Statistical analysis
Data entry and statistical analysis was done using the SPSS
ver.15 which included descriptive analysis, logistic regres-
sion for calculation of risk factors and dendrogram analysis.
Figure 1 was done by using the MS excel 2003 program.
Consent
Written informed consent was obtained from the
patients for publication of this manuscript.
Results
Analysis of nosocomial BSI
From January to December 2006, 2095 patients were
admitted to different ICUs at Assiut University Hospitals.
17.5% of those patients developed nosocomial infec-
tions. Among these nosocomial infections, nosocomial
BSI was the most common, accounting for 43% (n =
159). The rate of nosocomila BSI was 44 per 1000
patient days.
The rate of bacteremia among different ICUs is illu-
strated in table 1, which shows that the highest
percentages were in trauma ICU (17%) followed by
coronary care unit (13%) and general ICU 9.3%.
Figure 1
Variation in mortality rate by the organism which
causes primary bloodstream infection.
Table 1: Rate of bacteremia among different ICUs
ICU Frequency Percent (%)*
Trauma (n = 171) 29 17
Post operative (n = 100) 3 3
Chest (n = 375) 31 8.3
Medicine (n = 159) 6 3.8
General (n = 225) 21 9.3
Neurological (n = 190) 11 5.8
Coronary (n = 331) 43 13
Tropical (n = 260) 9 3.5
Neurosurgical (n = 284) 6 2.1
Total (n = 2095) 159 7.6
*(Percentage is calculated according to the number of patients admitted
to each ICU).
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Out of 159 bloodstream infections, 175 microorganisms
were isolated. Ninty percent (143/159) of infections were
monomicrobial, while (16/159) 10% of infections were
poly-microbial, containing 2 microorganisms. These
microorganisms and their distribution among different
I C U sa r es h o w ni nt a b l e2 .
Analysis of these isolates showed that Gram positive
organisms were reported in 69.1% (n = 121); MRSA was
the most prevalent (33/175, 18.9%), followed by
methicillin resistant coagulase negative Staphylococci
(16%). Gram negative bacilli were reported in (51/175,
29.1%). Klebsiella pneumoniae was the most common
(28/175, 10.3%) followed E coli (8.6%). Candida spp.
was reported only in (1.7%) of isolates.
Crude Mortality
Out of 159 patients with nosocomial BSI, 61 patients
died, representing a crude in-hospital mortality rate of
38% with a great variation in mortality rate by organism
(figure 1). The predisposing risk factors for BSI are
summarized in tables 3, which show that nosocomial
BSI was significantly associated with previous use of
antibiotics, diabetes, leucocytopenia, surgery, central
intravascular catheters and mechanical ventilation.
Antimicrobial Susceptibility testing
Antibiotics sensitivities of gram positive organisms
showed that the isolated organisms were mostly
sensitive to vancomycin (90.1%), amikacin (50.4%)
and chloramphenicol (43.8%), however gram negative
organisms were mostly sensitive to imipenem (90.2%),
amikacin (45.1%) and gentamicin (33.3%).
Analysis of Environmental Samples
Analysis of these samples showed that 210/475 (44.2%)
samples were clean and 265/475 (55.8%) were con-
taminated with different microorganisms. The distribu-
tion of these microorganisms appears in table 4, which
shows that the highest contamination rates were in
Trauma ICU (82%) followed by Chest ICU (77.8%) and
Post operative ICU 36 (75%).
Analysis of b-lactamase producers
Out of the 175 organisms which caused BSI, 29.1% (51/
175) were Gram negative bacilli. All these strains were
tested for the production of the b-lactamase enzyme by
the nitrocefin test, which indicated that 82.4% (42/51)
were b-lactamase producers.
Analysis of ESBL production
Preliminary screening showed that 78.4% (40/51) of
patients' isolates and 24.4% (33/135) of the environ-
mental isolates were considered as potential producers
of ESBLs.
Confirmatory tests (Combined Disk method, Double-
Disk Synergy "DDS" Tests, and ESBL E-Test) were carried
out to confirm the production of ESBL. Taking all
Table 2: Isolated microorganisms and their distribution among different ICUs.*
Organism
ICU Total No and
%O ft h e
organism in
all ICUs
(n = 175)
Trauma
n=3 3
Post operative
n=4
Chest
n=3 0
Medicine
n=6
General
n=2 5
Neurological
n=1 2
Coronary
n=4 8
Tropical
n=1 0
Neurosurgical
n=6
MS CNS 2(6.1%) 1(25%) 3(100%) 1(16.7%) 3 (12%) 4(33.3%) 9(18.8%) 2(20%) 0(0%) 25(14.3%)
MR CNS 6(18.2%) 1(25%) 2(*6.7%) 1(16.7%) 7(28%) 0(0%) 9(18.8%) 0(0%) 2(33.3%) 28(16%)
MSSA 3(9.1%) 0(0%) 5(16.7%) 2(33.3%) 2(8%) 0(0%) 3(6.3%) 1(10%) 2(33.3%) 18(10.3%)
MRSA 10(30.3%) 0(0%) 8(26.7%) 2(33.3%) 4(16%) 3(25%) 2(4.2%) 3(30%) 1(16.7%) 33(18.9%)
Streptococcus
pneumoniae
0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 4(8.3%) 0(0%) 0(0%) 4(2.3%)
Enterococcus
spp.
1(3%) 0(0%) 2(6.7%) 0(0%) 4(16%) 1(8.3%) 5(10.4%) 0(0%) 0(0%) 13(7.4%)
E coli 2(6.1%) 1(25%) 3(10%) 0(0%) 3(12%) 0(0%) 5(10.4%) 0(0%) 1(16.7%) 15(8.6%)
Klebsiella
pneumoniae
4(12.1%) 0(0%) 4(13.3%) 0(0%) 1(4%) 2(16.7%) 5(10.4%) 2(20%) 0(0%) 18(10.3%)
Klebsiella
oxytoca
0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 1(10%) 0(0%) 1(0.6%)
Enterobacter spp. 2(6.1%) 0(0%) 2(6.7%) 0(0%) 1(4%) 2(16.7%) 3(6.3%) 1(10%) 0(0%) 11(6.3%)
Acinetobacter
baumannii
1(3%) 0(0%) 0(0%) 1(16.7%) 0(0%) 0(0%) 2(4.2%) 0(0%) 0(0%) 4(2.3%)
Pseudomonas
aeruginosa
0(0%) 0(0%) 1(3.3%) 0(0%) 0(0%) 0(0%) 1(2.1%) 0(0%) 0(0%) 2(1.1%)
Candida spp. 2(6.1%) 1(25%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 3(1.7%)
*(n = total number of isolates in the ICU, percentage is calculated per number of isolates in each ICU).
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of patients' isolates and 14.8% (20/135) of the environ-
mental isolates were confirmed to be ESBL producers.
Determination of the type of b-lactamase by PCR
18 Klebsiella pneumoniae strains were isolated from
patients with nosocomial bacteremia and analyzed by
PCR. Our aim was to determine the probable type of
b-lactamase gene which is responsible for resistance.
It was found that SHV was the main type of b-lactamase
(61.1%).TEMwassecond(55.6%),CTX-M1(38.9%)was
third and there was no TOHO-1 group of b-lactamases.
Some Klebisella pneumoniae strains produced more than
o n et y p eo fb-lactamase. Two strains produced both
enzymes (TEM and SHV, 11.1%); one strain produced
TEM and CTX-M-1 enzymes (5.6%) and six strains
produced TEM, SHV and CTX-M-1 enzymes (33.3%).
Molecular typing by Random Amplified Polymorphic DNA
(RAPD)
-The PCR conditions allowed the amplification of 1–13
bands ranging in size from 220–2200 bp (figure 2, 3).
The strains were considered to be identical if they
differed by one band.
The RAPD pattern of the patient samples P17 and P18
were identical (figure 4).
The RAPD pattern of the environmental sample 33 is
identicalwiththatofenvironmentalsample34(figure4).
In addition, one RAPD group – environmental samples 25
and 26 with patient sample P10, showed three identical
patterns. By referring to the clinical data of these samples, it
was found that these samples were isolated from Trauma
ICU and occurred in the same time period. (figure 4).
These identical RAPD patterns suggest that the corre-
sponding strains constitute a clonal lineage [17].
Table 3: Odds ratio, 95% confidence intervals, and P values for
variables in logistic regression analysis of nosocomial BSI.
Risk factor P value OR 95.0% C.I.
Lower Upper
Previous administration
of antibiotics
0.002 7.43 3.34 9.542
Diabetes 0.001 1.050 1.010 1.751
Obesity 0.154 1.43 0.328 2.868
Male nutrition 0.528 1.353 0.529 3.459
Immune deficiency 0.287 2.562 0.454 14.470
Leucocytopenia 0.01 3.756 2.361 5.028
Surgery 0.005 6.702 2.882 12.283
Urinary Catheter 0.066 1.669 0.967 2.882
Peripheral I.V. Catheter 0.094 1.547 0.269 2.109
Central I.V. Catheter 0.013 5.654 3.184 8.821
Assisted nutrition 0.09 4.961 2.790 8.818
Mechanical Ventilation 0.027 4.833 3.959 9.506
Endotracheal tube 0.171 1.692 0.797 3.595
Drainage tube 0.128 1.122 0.026 2.571
Renal dialysis 0.538 1.471 0.043 3.158
Table 4: Distribution of pathogens isolated from the environment among different ICUs
Organism
ICU
Total
n = 475
Trauma
n=6 7
Post
operative
n=4 8
Chest
n=5 4
Medicine
n=5 3
General
n=5 0
Neurological
n=5 1
Coronary
n=5 0
Tropical
n=5 2
Neurosurgical
n=5 0
MS CNS 9(13.4%) 2(4.2%) 5(9.3%) 1(1.9%) 3(6%) 3(5.9%) 1(2%) 0(.0%) 4(8%) 28(5.9%)
MR CNS 4(6%) 0(.0%) 6(11.1%) 6(11.3%) 4(8%) 2(3.9%) 3(6%) 2(3.8%) 0(.0%) 27(5.7%)
MSSA 12(18%) 20(41.7%) 2(3.7%) 5(9.4%) 0(.0%) 3(5.9%) 0(.0%) 0(.0%) 0(.0%) 42(8.8%)
MRSA 0(.0%) 1(2.1%) 6(11.1%) 1(1.9%) 2(4%) 4(7.8%) 3(6%) 2(3.8%) 5(10%) 24(5.1%)
Enterococcus
spp.
1(1.5%) 2(4.2%) 1(1.9%) 0(.0%) 0(.0%) 1(2%) 0(.0%) 0(.0%) 0(.0%) 5(1.1%)
Ec o l i 16(23.9%) 9(18.8%) 1(1.9%) 1(1.9%) 1(2%) 3(5.9%) 1(2%) 0(.0%) 0(.0%) 32(6.7%)
Klebsiella
pneumoniae
4(6%) 2(4.2%) 15(27.8%) 2(5.7%) 1(2%) 5(9.8%) 3(6%) 0(.0%) 4(8%) 36(7.6%)
Pseudomonas
aeruginosa
5(7.5%) 0(.0%) 3(5.6%) 2(3.8%) 3(6%) 2(3.9%) 1(2%) 0(.0%) 1(2%) 17(3.6%)
Candida spp. 0(.0%) 0(.0%) 0(.0%) 3(5.7%) 0(.0%) 0(.0%) 0(.0%) 1(1.9%) 0(.0%) 4(0.8%)
Nonlactose
fermenter
0(.0%) 0(.0%) 3(5.6%) 10(19%) 14(28%) 0(.0%) 0(.0%) 0(.0%) 1(2%) 28(5.9%)
Proteus spp. 4(6%) 0(.0%) 0(.0%) 0(.0%) 0(.0%) 6(11.8%) 9(18%) 3(5.9%) 0(.0%) 22(4.6%)
Contamination
rate
55(82%) 36(75%) 42(77.8%) 31(58.4%) 28(56%) 29(56.8%) 21(42%) 8(15.3%) 15(30%) 265(55.8%)
*(n = number of samples obtained from each ICU, percentage is calculated according to number of samples obtained from each ICU.
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In the present study, the rate of nosocomial BSI per 1000
patient days was 44. These results were higher than those
reported by Sligl et al. [18] in Canada. The highest
number of cases wasreported form the coronary ICU (43/
159 patients).
In this study we tried to assess the risk factors associated
with BSI. Higher BSIs were found among diabetic
patients with a statistically significant difference, which
can be explained by the low immunity of diabetic
patient and their high vulnerability to infections.
In addition, there was a tendency towards increasing
the percentage of BSI among patients with previous
prescriptions of antibiotics and mechanical ventilation.
This is supported by findings of Sǔljagic et al.[ 2 ]
who reported that risk factors for acquisition of BSI
in the ICU included previous prescription of anti-
biotics, mechanical ventilation and the use of
nasogastric tubes. In conclusion, multivariate analysis
demonstrated that previous administration of
antibiotics; diabetes, central intravenous lines, leuco-
cytopenia, and surgery were independently associated
with BSI.
Figure 2
RAPD patterns of: 36 K. pneumoniae isolated from the environment.
Figure 3
RAPD patterns of: 18 strains isolated from patients.
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that Gram positive organisms accounted for 69% of
isolates, while Gram negative isolates accounted for 29%
of them. We found a shift to Gram positive organisms as
reported in many countries.
The leading pathogens causing clinically significant
nosocomial BSI in our institution were coagulase
negative staphylococci (30.3%), S. aureus (29.2%) and
Klebsiella pneumoniae (10.3%). Our results are consistent
with the results of other surveillance studies. Data from
the SCOPE (Surveillance and Control of Pathogens of
Epidemiologic Importance) project revealed that the
most common pathogens causing nosocomial BSI were
coagulase-negative staphylococci (32%) and S. aureus
(16%) [19]. In addition, data published from the
National Nosocomial Infections Surveillance System
(NNIS) for ICU-associated primary bloodstream infec-
tions identified coagulase-negative staphylococci (37%)
and S. aureus (12.6%) as the leading pathogens [20].
Other studies by Warran et al. [21] also confirmed the
emergence of Gram-positive pathogens in nosocomial
BSI. This increase in the frequency of coagulase-negative
staphylococcal BSI isolates has occurred concurrently
with the increased use of invasive intravascular catheters.
In addition, the trend for coagulase negative
staphylococci may reflect a change from regarding
these organisms as skin flora to viewing them as
clinically significant.
Gram negative pathogens were lower on the rank of
organisms and included Klebsiella pneumoniae (10.3%)
which was the most commonly isolated Gram negative
organism, followed by Ec o l i(8.6%) and Enterobacter spp.
(6.3%). These results are similar to those of other recent
nosocomial BSI studies where these organisms have been
among the leading Gram-negative pathogens [3]. Anti-
biotic resistance is a growing problem in hospitals
everywhere.
In the present study, 65% of the S. aureus blood-stream
isolates are resistant to methicillin. The incidence of
methicillin resistance was also high among coagulase-
negative staphylococci, with 53% of CNS being resistant
to methicillin. Our finding coincides with that reported
in a French general hospital, where the MRSA rate was
46% [22].
Gram negative rods showed high resistance rates to the
majority of antibiotics. This may be explained by the late
introduction of infection control programs in our
hospital, the site where our study was performed (ICUs
Figure 4
The corresponding dendrogram. 1Æ36 = environmental samples, P1ÆP18 = patient samples.
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(page number not for citation purposes)only) and the high percentage of extended spectrum b
lactamases among Gram negative bacilli (64.7%), which
limits the therapeutic choices in infections caused by
such strains due to two broad factors: cross-resistance
(e.g. to aminoglycosides, co-trimoxazole or fluoroqui-
nolones) and the spectrum of these enzymes.
In our study, the crude in-hospital mortality rate
associated with nosocomial BSI was 38%. Similarly, in
a nationwide study, a crude mortality rate as high as 27%
has been reported [3].
In addition, the present study identified a great variation
of crude mortality rate by pathogen. Higher rates were
obtained with MRCNS (29%) compared to MSCNS
(4%), with MRSA (49%) compared to MSSA (6%), with
VRE (38%) compared to VSE (20%) and with ESBLs
(76%) compared to Non ESBLs (17%). Also, investiga-
tors in Canada have compared the mortality between
MRSA and MSSA bacteremia and reported a higher
mortality in the MRSA group (36 vs. 20%), but this
failed to achieve statistical significance [23]. Further-
m o r e ,t h em o r t a l i t yo fM R S Ab a c t e r e m i aw a s1 1 . 8 %
versus 5.1% in MSSA with no statistical significance.
These data suggest that the mortality of MRSA bacter-
emia exceeds that of bacteremia with MSSA.
Analysis of environmental samples showed that 265
samples (55.8%) were contaminated with different micro-
organisms. The most common contaminating organisms
wereMSSA42(8.8%),followedbyK.pneumoniae36(7.6%)
and E. coli 32 (6.7%). The highest contamination rate
occurred in Trauma ICU (82%), followed by Chest ICU
(77.8%) and Post operative ICU (75%).
Correlation between nosocomial BSI rate and environ-
mental analysis showed that the highest rate of BSI was
in Trauma ICU (17%). These results highlighted the role
of the environment in the spread of nosocomial BSI and
agreed with Karanfil et al. [24] who found that the
inanimate contaminated environment which induces
surfaces and surgical instruments is a potential source of
nosocomial BSI. Detection of ESBL production was done
by preliminary screening that depends on reduced
susceptibility to one or more of cefpodoxime, ceftazi-
dime, aztreonam, cefotaxime or ceftriaxone. This showed
that 78.4% of patients' isolates and 24.4% of the
environmental isolates were considered as potential
producers of ESBLs.
Taking all confirmatory tests into account, a total of
64.7% of patients' isolates and 14.8% of environmental
isolates were confirmed to be ESBL producers. Analysis
of the patients' isolates showed that similar results were
obtained by the Combined Disk method, the Double-
Disk Synergy "DDS" test with clavulanic acid and the
ESBL E-Test, with 26 isolates being found to be ESBL
producers. The double disk synergy test using tazobac-
tam revealed an additional 7 strains that were positive
for ESBL. This suggests that those 7 strains produce an
ESBL enzyme and a AmpC-enzyme. With these organ-
isms, clavulanic acid may induce expression of high-level
AmpC production and may then antagonize rather than
protect the antibacterial activity of the partner b-lactam
[ 2 5 ] .T h u s ,t h ep r e s e n c eo fa nE S B Lc a nb em a s k e db yt h e
expression of an AmpC-type enzyme in the same strain
(by masking any synergy with ESBLs) [26]. As a result,
when testing for ESBL production in these organisms, we
should consider using sulfones such as tazobactam and
sulbactam as b-lactamase inhibitors [27]. Although the
exact reasons are not completely understood, the
pressure to use non-b-lactam antibiotics may be respon-
sible for the co-existence of ESBL and AmpC. The genes
coding for ESBLs and other non-b-lactam resistance
genes (e.g. aminoglycosides or co-trimoxazole) often
reside within the same conjugative plasmid and there-
fore are transmitted together from one strain to another
and can be co-selected under the pressure of prior multi-
drug usage [28].
In our study, the percentage of extended spectrum
b-lactamase producing Gram negative bacilli among
patients with BSI was 64.7%. The prevalence and relative
distribution of ESBLs vary depending on the facility and
the level of care taken to control nosocomial BSI. These
factors also vary with geographic location and time [29].
During our study, 14.8% of environmental Gram-
negative isolates were ESBL-producers. These organisms
are considered a potential source of primary blood-
stream infection with ESBL-producing organisms which
have limited therapeutic options, are multidrug resistant,
and lead to poor outcomes [30]. The distribution of
environmental ESBL-producing organisms showed that
the highest rate was in the Coronary care unit (12%)
followed by Trauma ICU (7.5%). Also, the highest rates
of nosocomial BSI with ESBL-producing organisms were
in the Coronary care unit (3.3%) and Trauma ICU
(2.9%). These results confirm the serious role of the
hospital environment in the transmission and spread of
infections.
In the present study, the type of b-lactamase gene was
determined among Klebisella pneumoniae strains by using
a polymerase chain reaction, which showed that SHV
was the main type of b-lactamase, followed by TEM and
CTX-M1. There was no TOHO-1 group of b-lactamases.
Some Klebisella pneumoniae strains produced more than
o n et y p eo fb-lactamase; TEM and SHV were produced by
2 isolates, while TEM and CTX-M-1 were produced by
BMC Research Notes 2009, 2:76 http://www.biomedcentral.com/1756-0500/2/76
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(page number not for citation purposes)one isolate. Moreover, six strains produced TEM, SHV
and CTX-M-1 enzymes.
SHV was the main type of b-lactamase, and TEM was
second. Although we could not determine the subtype of
TEM or SHV, these results at least suggest that TEM or
SHV-type ESBLs probably exist. Similar results were
reported by Bradford [ 2 6 ]w h oo b s e r v e dt h a tT E M -a n d
SHV-type ESBLs remain more common in North
America.
In this work, we investigated unrelated strains from both
the environment and infected patients. We found 50
RAPD genotypes among 54 K. pneumoniae studied, which
demonstrated the high discriminatory power of RAPD
with primer usage.
T w oR A P Dg r o u p ss h o w e dt w oi d e n t i c a lp a t t e r n s .
The clonal similarity between two patients in the same
chest unit who were admitted at the same time and
showed the same antibiogram suggests that this strain
was transmitted from one patient to the other (may be
the role of contaminated instruments or contaminated
hands of hospital staff). Similar findings were reported
by Lopesa et al. [17] who found 4 strains isolated from an
outbreak with K. pneumoniae to be related by RAPD
analysis, suggesting clonal linearity.
T h o s et w os t r a i n sw e r ei s o l a t e df r o mt h ec h e s tI C U
Environmental samples ando c c u r r e di nt h es a m et i m e
period which indicates the importance of implying
infection control measures on cleaning surfaces.
One of the interesting findings in this study is that 1
RAPD group, environmental samples 25 and 26 with the
patient sample P10, showed 3 identical patterns. By
referring to the clinical data of these samples, it was
found that these samples were isolated from the Trauma
I C Ua n do c c u r r e di nt h es a m et i m ep e r i o d .T h e
environmental samples could have been transmitted
to the patient, or they may have been a focus of infection
to other patients which are highly susceptible due to
different risk factors and the ICU setting.
The RAPD analysis indicated that pathogenic K. Pneu-
moniae strains comprise a genetically high variable group
of organisms. These data confirmed the observation of
Lai et al. [30], who stated that based on the distribution
of different nucleotide sequences; the pathogenic
K. Pneumoniae population was highly heterogeneous.
In summary, K. pneumoniae infections have been caused
by a variety of strain genotypes that could be transmitted
from one patient to another in different ways, and it is
important to monitor such strains closely to prevent
their spread. In this situation, the design of rational
infection control measures that require the adoption of
new antibiotic policies in addition to improving hospital
hygiene becomes even more challenging [17].
Limitations of the study
The large number of patients did not align with the
limited number of investigators. As a result, we
recommend the development of a continuous data
base registration system for acquired infection data.
This will markedly help investigators in the future by
allowing them to have access to a large set of data over
many years. It will also help the detection of the effects
of currently active hospital control measures.
Conclusion
Nosocomial BSI represents a current problem in Assiut
University Hospitals. Problems associated with BSI
include infection with multidrug resistant pathogens
(especially ESBLs) which are difficult to treat and are
associated with increased mortality. Carbapenems are
the most active and reliable treatment options for
infections caused by ESBL isolates, however, overuse of
carbapenems may lead to resistance of other gram-
negative organisms.
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